Go to the main content

frontend.sr-only_#{element.icon}: Otfried-Müller-Str. 10, 72076 Tübingen

frontend.sr-only_#{element.icon}: Auf der Morgenstelle 15, 72076 Tübingen


frontend.sr-only_#{element.icon}: +49 7071 29-82834

frontend.sr-only_#{element.icon}: +49 7071 29-4391

frontend.sr-only_#{element.icon}: PBI@med.uni-tuebingen.de

About us

At the University Hospital Tübingen, the translationally oriented Department of Peptide-based Immunotherapy, led by Prof. Juliane Walz, studies and develops T cell-based immunotherapies for infectious and tumor diseases. Our main goal is to quickly transfer  promising research findings in the field of peptide-based immunotherapy into clinical applications for patients.

As a result, our department includes both  an application-oriented research area, which investigates the mechanisms of T cell-mediated immune recognition of tumors and virus-infected cells via HLA-presented peptides and develops new immunotherapy concepts, as well as a Wirkstoffpeptidlabor, which in a next step produces the peptides for clinical trials.

The innovative concepts are then evaluated in phase I/II cinical trials in collaboration with the Clinical Cooperation Unit (CCU) Translational Immunology.

Our team

Our team

Head of Department

Portrait photo

Prof. Dr. med. Juliane Walz

W3 Professor Peptide-based Immunotherapy
Medical Director KKE Translational Immunology

Person profile: More about the person

Empty placeholder

Personal Assistant:
Anna-Carmen Hentschke

Phone number: +49 7071 29-87305

Fax number: +49 7071 29-4391

E-mail address: Anna-Carmen.Hentschke@med.uni-tuebingen.de

E-mail address: PBI@med.uni-tuebingen.de

Team photo of the working group


In recent years, immunotherapy, i.e. the specific induction of anti-tumor immune responses, has revolutionized the treatment of cancer. However, such immunotherapeutic approaches are not yet available for all cancer entities and many patients often do not respond or only respond for a limited time to currently available therapeutic options. Here, peptide-based immunotherapy represents a comparatively low side-effect option for inducing specific immune responses against tumor cells in patients.

More about research


The Wirkstoffpeptidlabor of the University of Tübingen within the Department of Immunology has over 25 years of experience in the production of synthetic peptides. It specializes in the efficient production of small quantities of peptides in pharmaceutical quality for use in personalized peptide vaccination in the context of phase I and II clinical trials. Since March 2012, the active ingredient peptide laboratory has held a GMP certificate from the Regierungspräsidium Tübingen as an active ingredient manufacturer according to § 64 AMG.

Learn more

Peptide laboratory samples

Clinical studies

The peptide vaccines and T cell activators developed and produced in our department are tested in clinical trials here at the University Hospital and at cooperating partner sites. For this purpose, we work closely with the Clinical Cooperation Unit (CCU) Translational Immunology. The direct link between research and therapy enables us to provide our patients with newly developed immunotherapeutic treatment options for tumor diseases and infectious diseases at an early stage and to offer individual immunotherapy concepts.

An overview of clinical trials can be found on the homepage of the CCU.

Learn more

Our services

Education & Career

As a result of the recent clinical success of immunotherapeutic approaches in oncology, the topic of immunotherapy is becoming increasingly prominent in the curriculum. Therefore, the Department of Peptide-based Immunotherapy participates in numerous courses and curricula of the study programs Human Medicine, Biochemistry, Biology and Molecular Medicine. Thereby, it is important for us not only to create the basic understanding of immunotherapy, but also to convey the specifics of translationally oriented research.

Internships, Bachelor, Master and PhD Theses

The Department of Peptide-based Immunotherapy offers the opportunity to gain insights into basic immunological research and its translational implementation within the framework of internships, bachelor and master theses as well as medical and scientific doctoral theses.

Residents and specialists in rotation

Together with the CCU Translational Immunology, the Department of Peptide-based Immunotherapy offers research-interested residents and specialists the opportunity to gain experience in the development and conduct of clinical trials within the framework of a rotation.

Unsolicited applications

from committed students to carry out their bachelor's or master's thesis as well as for medical or scientific doctoral theses are welcome. We also welcome applications from young scientists with a PhD who are interested in our field of research.


23. November 2021

Eigenentwickelter Impfstoff gegen SARS-CoV-2 zeigt starke Immunantwort

Am Universitätsklinikum Tübingen wurde im November 2020 unter Leitung von Prof. ...

12. April 2022

Covid vaccines didn’t work for many cancer patient…

23. July 2022

25. Krebsinformationstag (Präsenz und online)

für Patientinnen und Patienten, Angehörige und Interessierte


Follow us on Twitter

Cookie Einstellungen
Bitte treffen Sie eine Auswahl um fortzufahren.
Weitere Informationen zu den Auswirkungen Ihrer Auswahl finden Sie unter Hilfe.
Um fortfahren zu können, müssen Sie eine Cookie-Auswahl treffen.

Cookies zulassen:
Wir setzen das Analysetool Google Analytics ein, um Besucher-Informationen wie z.B. Browser, Land, oder die Dauer, wie lange ein Benutzer auf unserer Seite verweilt, zu messen. Ihre IP-Adresse wird anonymisiert übertragen, die Verbindung zu Google ist verschlüsselt.

Nur notwendige Cookies zulassen:
Wir verzichten auf den Einsatz von Analysetools. Es werden jedoch technisch notwendige Cookies, die eine reibungslose Navigation und Nutzung der Webseite ermöglichen, gesetzt (beispielsweise den Zugang zum zugangsbeschränkten Bereich erlauben).

Sie können Ihre Cookie-Einstellung jederzeit auf der Seite Datenschutzerklärung ändern. Zum Impressum.


Cookies zulassen Nur notwendige Cookies zulassen